Status:
ENROLLING_BY_INVITATION
Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia
Lead Sponsor:
Charles University, Czech Republic
Conditions:
Eating Disorder
Bulimia Nervosa
Eligibility:
FEMALE
18-30 years
Phase:
PHASE2
Brief Summary
This study evaluates the addition of Acipimox or placebo to exercise on growth hormone release and ghrelin secretion in bulimic patients and in healthy women. Two groups of participants will receive A...
Detailed Description
Acipimox and exercise each increase growth hormone release, but they do so by different mechanisms. Acipimox is an anti-lipolytic drug and increases growth hormone release by decreasing free fatty ac...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of bulimia nervosa
- Body mass index (BMI) between 18 and 23 kg/m2
Exclusion
- History of heart disease
- History of bleeding disorders
- Subjects with diabetes type 1 or 2, hypo- or hyperthyroidism
- Subjects with hepatogastroenteric disease
- Pregnant, trying to become pregnant or breast feeding
- Patients with other psychiatric diseases
Key Trial Info
Start Date :
May 6 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 20 2026
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03338387
Start Date
May 6 2003
End Date
December 20 2026
Last Update
February 19 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.